Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ask Labs currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner in 1 distinct art unit. The concentrated nature of this activity allows for a highly targeted prosecution strategy that addresses a single set of technical issues.
ARIANI, KADE is the busiest examiner, handling 1 pending office action. This single action accounts for the entire pending volume of the portfolio. For a practitioner, the fact that 1 distinct examiner is responsible for the 1 pending office action means that the outcome depends on a single individual's interpretation of the law and facts. This requires a careful analysis of the specific feedback provided by ARIANI, KADE.
The presence of 1 distinct art unit ensures that the 1 pending office action is subject to a specific set of technical standards. Practitioners should focus on the specific requirements of the 1 distinct examiner to advance the 1 pending matter. This streamlined workload facilitates a clear path toward resolving the portfolio's current prosecution hurdles. The simplicity of having 1 pending office action allows for an efficient allocation of resources toward a single goal.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 75.0% | +32.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273584 | NOVEL MICROALGAE WITH HIGH PRODUCTIVITY OF ZEAXANTHIN AND LUTEIN | ARIANI, KADE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273584 | NOVEL MICROALGAE WITH HIGH PRODUCTIVITY OF ZEAXANTHIN AND LUTEIN | ARIANI, KADE | 1651 | §112 | Final Rejection | — | Pending | Jul 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsk Labs has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kade Ariani has the most, with 1 of Ask Labs's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
